Work

Association between Diabetes and Liver Cancer: A systematic Review and Meta-Analysis of Case-Control and Cohort Studies

Year: 2023
Type: review
Abstract: Methods: Literature searches, using Cochrane and PRISMA guidelines, focused on studies published between September 2012 to September 2022, conducted on PubMed Central, and a population, exposure, comparator, and outcome (PECO) approach applied. The primary analysis was the association of diabetes with the risk of liver cancer, and subgroup analysis was perfumed using gender, race, and study design. Background and Aims: Diabetes is a chronic (long-lasting) health condition that affects how your body turns food consumed into energy. Previous research has linked diabetes with liver cancer-; for example, cohort studies have consistently shown an increased liver cancer risk in people with type 2 diabetes. About 1 in 10 people in America (37.3 million) have diabetes, and its prevalence is increasing, so there is concern that this trend could exacerbate the rising incidence of liver cancer. The various ways in which diabetes contributes to HCC need to be further investigated. The aim of this study was to investigate the association between diabetes and the risk of liver cancer. Conclusion: Through this study, I was able to show a significant association between type 2 diabetes and the risk of liver cancer in all studies I analyzed, as well as between sub-group analyses. The ways in which diabetes contributes to HCC need to be further investigated in future studies. Results: Of 5649 studies, forty-seven were eligible and included in this analysis. The pooled overall risk measure showed that type 2 diabetes was associated with an increased risk of liver cancer (RR=1.59, 95% CI: 1.36-1.87, I²=52.53%, p=0.0002), compared to non-diabetes. Out of forty-seven studies, 32 (80%) had a statistically significant association between diabetes and the risk of liver cancer. Subgroup analysis showed an increased risk of liver cancer among diabetic patients (RR =1.54, 95%CI: 1.07-2.20, I²=61.31%, p=0.0037) in females, (RR=1.80, 95%CI: 1.30-2.49, I²=60.25%, p=0.0158) in males, (RR=2.80, 95%CI: 1.63-4.80) in whites, (RR=1.31, 95%CI: 0.85-2.03) in blacks, (OR=1.63, 95% CI: 1.23-2.16, I²=61.59%, p=0.0001) in case-control studies, and (RR=1.63, 95%CI: 1.36-1.97, I²=43.93%, p=0.0419) in cohort studies compared to no-diabetic patients. There was no significant heterogeneity among African Americans (I²=0%, p=0.8350), and Whites (I²=0%, p=0.8399).
Author: Seeh, David Odhiambo
Language: English
Open Access status: green
OpenAlex ID: W6998840413
FWCI:
Cites: 71
Cited by:
Related to: 9